Resources search

Mental health funding and the SDGs What now and who pays?

MACKENZIE, Jessica
KESNER, Christie
May 2016

Expand view

"This report provides an overview of who is currently funding mental health and who isn’t, but could be. It is a synthesis of research previously conducted in this field and analyses both existing and new funders. It highlights how little information there is on what donors are spending on mental health globally, what types of activities are funded and why funding mental health delivers a variety of benefits, and it suggests how to frame the issue to encourage more investment".

2015 global reference list of 100 core health indicators

WORLD HEALTH ORGANIZATION (WHO)
2015

Expand view

“The Global Reference List of 100 Core Health Indicators is a standard set of 100 indicators prioritized by the global community to provide concise information on the health situation and trends, including responses at national and global levels. It contains indicators of relevance to country, regional and global reporting across the spectrum of global health priorities relating to the post-2015 health goals of the Sustainable Development Goals (SDGs). These include the Millennium Development Goals (MDGs) agenda, new and emerging priorities such as noncommunicable diseases, universal health coverage and other issues in the post-2015 development agenda.”

World health statistics 2010

WORLD HEALTH ORGANIZATION (WHO)
2010

Expand view

This annual compilation of health-related data for the World Health Organization's 193 member states, includes a summary of the progress made towards achieving the health-related Millennium Development Goals (MDGs) and associated targets

Universal coverage of health services: tailoring its implementation

CARRIN, Guy
MATHAUER, Inke
XU, Ke
EVANS, David
2008

Expand view

In 2005, the Member States of WHO adopted a resolution encouraging countries to develop health financing systems capable of achieving and/or maintaining universal coverage of health services – where all people have access to needed health services without the risk of severe financial consequences. In doing this, a major challenge for many countries will be to move away from out-of-pocket payments, which are often used as an important source of fund collection. Prepayment methods will need to be developed or expanded but, in addition to questions of revenue collection, specific attention will also have to be paid to pooling funds to spread risks and to enable their efficient and equitable use. Developing prepayment mechanisms may take time, depending on countries’ economic, social and political contexts. Specific rules for health financing policy will need to be developed and implementing organizations will need to be tailored to the level that countries can support and sustain. In this paper we propose a comprehensive framework focusing on health financing rules and organizations that can be used to support countries in developing their health financing systems in the search for universal coverage.

Mexico Forum 8

GLOBAL FORUM FOR HEALTH RESEARCH
February 2005

Expand view

The Global Forum for Health Research aims at addressing the "10/90 gap": less than ten per cent of research funds are devoted to 90 per cent of the world health needs. This CD-ROM contains the full text of papers and posters presented at Forum 8 in Mexico City in 2004. Forum 8 gathered around 900 participants from 450 institutions in 109 countries. Participants represented governments, multilateral and bilateral aid agencies, international and national foundations and NGOs, women's organizations, research institutions and universities, the private sector and the media. Topics covered include health research, disease prevention, child mortality, maternal health, substance abuse, mental and neurological health

The world medicines situation

WORLD HEALTH ORGANIZATION (WHO)
2004

Expand view

The publication provides an accessible source of information on the pharmaceutical situation at global and national levels. It assembles the available evidence regarding the production and consumption of medicines, and a range of issues in national medicines policies, including the level of people's access, patterns of use, the challenges of medicines regulation and promoting rational use. Numerous different sources of data are used. A 32-page annex of statistics is included. The target readers are researchers, academics and analysts concerned with medicines and public health

Ghana national drug policy

Ministry of Health, Ghana
2004

Expand view

This policy includes the following sections: a situational analysis of drug selection; drug procurement, storage and distribution; drug financing; quality assurance; local manufacture of pharmaceutical and traditional medicinal products; rational drug use; global trade and pharmaceuticals; emerging diseases and pharmaceuticals; human resource development for drug management; traditional medicinal products; research and development; and implementation of the policy

Collateral damage : the health and environmental costs of war on Iraq

SALVAGE, Jane
November 2002

Expand view

This is a report on the impact of the 1900-1991 Gulf War on the Iraqi population. An estimated 205,000 Iraqis died in 1991, and an excess of 47,000 deaths among children under five were reported from January to August 1991. The consequences of armed conflicts are generally felt for decades, as the natural environment and essential infrastructure (including health services) are damaged or destroyed. Iraq's infrastructure was extensively damaged, and biological and chemical pollutants were widely dispersed. Sanctions, the Oil-for-Food Programme, and No-Fly Zones undermined recovery and reconstruction efforts in the aftermath of the war

South African health review 2001

HEALTH SYSTEMS TRUST (HST)
March 2002

Expand view

This is a comprehensive, authoritative and independent review of the South African health system. It is published annually and this year's edition is is made up of 17 chapters grouped into four themes: listening to voices, equity, information for health, accountability and transformation. The review acts as a barometer for assessing the transformation processes and their impact on provision of equitable health care to all in South Africa

Improving health outcomes of the poor : report of working group 5 of the Commission on Macroeconomics and Health

COMMISSION ON MACROECONOMICS AND HEALTH. Working Group 5
2002

Expand view

Analyses health sector issues in the developing world including: avoidable mortality, prioritisation of interventions, overcoming constraints of scaling up, and cost of scaling up interventions. Specific health issues addressed include maternal and perinatal mortality, childhood illness, malnutrition, malaria, TB, smoking, and hiv/aids. Includes statistics and graphs, diagrams and tables to illustrate points

Executive summary : globalisation and liberalisation of healthcare services. WTO and the General Agreement on Trade in Services

BALASUBRAMANIAM, K
2000

Expand view

This paper begins with a description of the evolution of the TRIPs Agreement. The TRIPs Agreement together with Trade Related Investment Measures (TRIMs) have taken away the powers of economic decision making from the national governments and handed them to the dominant actors in the international market place, namely the transnational corporations (TNCs). The international economic order has been radically restructured by the TRIPs Agreement which encompasses virtually the entire economic spectrum. To understand fully the implications of WTO/TRIPs Agreement on the access of drugs to consumers in the ASEAN region, this paper presents data on the pharmaceutical industry in the region and globally. All these countries have now changed their national legislation on patents in accordance with TRIPs Agreement. They will provide patent protection for pharmaceutical products. These countries will not be able to manufacture any drug under patent protection for a period of 20 years, resulting in the multinational drug companies having a monopoly of all patent protected drugs, leading to the collapse of the pharmaceutical industry in developing countries. The paper concludes that the only way to avoid this and strengthen the pharmaceutical sector in developing countries is through compulsory licensing and parallel imports, which are allowed in the TRIPs Agreement. This will enable consumers in the ASEAN countries to access affordable pharmaceuticals. This, consumers believe, is a short-term solution. The paper also gives a longterm solution, involving a shake up of the international governance system

Programme report 1996

WORLD HEALTH ORGANIZATION (WHO). Global Programme for Vaccines and Immunization
1997

Pages

E-bulletin